The rise of Canadian cannabis stocks over the past three years is nothing short of stunning, and investors who missed the rally to this point are wondering which companies might be attractive for long-term potential gains.
Formerly known as Hydropothecary, this Quebec-based medical marijuana producer is positioning itself to be a major player in the Canadian market once recreational sales become legal in October.
The company just announced a three-year distribution agreement that will see HEXO partner with Metro Supply Chain to manage a Montreal-based warehouse and distribution centre to handle Quebec adult-use online orders.
Earlier this month, HEXO announced the purchase a 25% interest in a two-million-square-foot facility in Belleville, Ontario. The site will be used as part of HEXO’s hub-and-spoke distribution model and will give the company the space it needs to manufacture advanced cannabis consumer products that are expected to be a large part of the overall market. HEXO is developing cosmetics, edibles, and non-alcoholic beverages as part of its broader cannabis strategy.
On the beverage front, HEXO has partnered with Molson Coors Canada to set up a new joint-venture company that will target the cannabis-infused beverage market. The move is viewed as strategically important, after Canopy Growth partnered with Corona-maker Constellation Brands.
Aurora Cannabis went on a buying spree this year, acquiring two major competitors in a bid to become Canada’s top medical marijuana company. The $1.1 billion purchase of CanniMed in January and the $2.5 billion takeover of MedReleaf made Aurora Cannabis a powerful force in the industry with 570,000 kg per year of funded production capacity.
Aurora Cannabis is also targeting the global market and already has sales and operations serving 14 countries.
The stock had been under pressure for most of 2018 until Constellation Brands announced its $5 billion second-phase investment in Canopy Growth in August. The news put a tailwind behind Aurora Cannabis, as investors speculated it would be next to announce a partnership with a major beverage company.
Rumours then emerged that Aurora Cannabis was in talks with Coca-Cola. This provided an extra boost to the stock, but no deal has been announced.
Is one a better bet?
HEXO has a market capitalization of $1.6 billion compared to more than $12 billion for Aurora Cannabis. As the industry evolves, further consolidation should be expected, so I wouldn’t be surprised to see HEXO become a takeover target. If you want to focus on Canada and are looking for a potential shot at a takeover premium, HEXO might be the way to go.
Otherwise, Aurora Cannabis has the scale and the international reach to be a long-term global player, and any announcement on a partnership with a beverage giant could send the shares even higher.
Overall, both stocks are quite expensive after the rallies that occurred in the past month, so investors should anticipate some volatility and keep positions small relative to their total portfolio.
Additional disruptor opportunities are worth considering in the market today.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Andrew Walker has no position in any stock mentioned. The Motley Fool owns shares of Molson Coors Brewing.